RCS - Agronomics Limited - EVERY raise US$ 55 million in fresh capital

AgronomicsAnnouncement

10/11/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251110:nRSJ7513Ga&default-theme=true

RNS Number : 7513G  Agronomics Limited  10 November 2025

Agronomics Limited (https://agronomics.im/)

("Agronomics" or the "Company")

 

EVERY raise US$ 55 million in fresh capital ahead of nationwide U.S. rollout

 

Agronomics Limited (LSE: ANIC), a leading listed company focused on clean
food, is pleased to report that portfolio company, the EVERY Company
("EVERY"), has successfully closed a US$ 55 million Series D financing round.
The round, led by McWin Capital Partners through the McWin Food Tech Fund,
included participation from Main Sequence, Bloom8, TO.VC, Minerva Foods,
Grosvenor Food & Ag, New Agrarian Company Limited (an affiliate of
Agronomics), and SOSV.

 

This funding will support the expansion of EVERY's manufacturing capacity, as
it aims to move to profitability and scale its impact within the US$ 270
billion
(https://www.researchandmarkets.com/report/eggs?srsltid=AfmBOooiOCviCPotPrAisXrtVrTHraZs0keJOn8s73ulzWAfYq-NU94u)
egg marke
(https://www.researchandmarkets.com/report/eggs?srsltid=AfmBOooiOCviCPotPrAisXrtVrTHraZs0keJOn8s73ulzWAfYq-NU94u)
t.

 

EVERY, based in San Francisco, produces egg proteins using precision
fermentation. Its FDA-approved product line includes OvoPro™ (ovalbumin,
formerly EVERY EggWhite) which replicates the functionality of egg and egg
whites, and OvoBoost™ (formerly EVERY Protein), a highly soluble, neutral
tasting protein suitable for fortifying a wide variety of food and beverage
products including coffees, juices, sodas, syrups and baked goods.

 

In early November, EVERY's precision fermented egg protein ingredient will be
featured in a new launch at Walmart, the world's biggest retailer, making it
available throughout the U.S.

 

Jim Mellon, Executive Chair of Agronomics, commented:

"EVERY's successful funding round underscores the transformative potential of
precision fermentation in solving real-world food supply challenges. With
volatile egg prices and traditional supply chains under pressure, EVERY offers
a scalable, resilient, and sustainable alternative that meets the needs of the
world's largest food producers. We are delighted to be joined by a cohort of
respected investors, who know that EVERY can deliver consistent, high-quality
protein at an industrial scale and play a leading role in the future of
sustainable food production. This is exactly the kind of innovation that
aligns with our wider strategy of backing technologies capable of redefining
entire markets."

 

Agronomics' Investment

Agronomics first invested in EVERY on the 4th of November 2021, and to date
has invested a total of £5.9 million, which, subject to audit, is currently
carried at approximately £5.9 million. This position represents around 4.02%
of Agronomics' most recently reported Net Asset Value of £145.3 million as of
30 June 2025. This fundraise is not expected to impact on the carrying value
of Agronomics' holding in EVERY.

 

The full announcement is set out below, with no material changes:

 

EVERY Raises $55 Million in Fresh Capital Ahead of Nationwide Rollout

Funding to accelerate large scale U.S. expansion with multinational customers
beginning this month, amid growing demand from food companies to stabilize
their egg supply chains.

 

The EVERY Company, a biotechnology leader pioneering precision fermentation
for highly functional proteins, today announced that it has successfully
closed on $55 million in Series D financing. The round was led by McWin
Capital Partners, through the McWin Food Tech Fund, with participation from
Main Sequence, Bloom8, TO.VC, Minerva Foods, Grosvenor Food & Ag, New
Agrarian, SOSV, and more.

 

Proceeds from the Series D will be used to expand manufacturing capacity, move
to profitability, and further expand its reach across the $270B egg market -
particularly in the high-volume bakery segment.

 

"This new injection of capital will allow us to make good on our promise of
making products that are accessible to everyone - in every state, every city,
and every grocery store," said Arturo Elizondo, Co-Founder and CEO of EVERY.
"This milestone fundraise is a powerful validation of our ambitions and we're
grateful for the trust of our incredible investors."

 

Mass Market Adoption and Commercial Expansion

This announcement underlines the strength and market viability of EVERY's
innovative approach to functional proteins, with its ingredients successfully
commercialized across online platforms, retail markets, and foodservice
channels as early indicators of market demand. Building on this momentum,
EVERY is now strategically focused on scaling for mass-market adoption.
Starting this month, EVERY's proteins will be featured in products launching
in Walmart, the world's biggest retailer, and available on shelves nationwide.

 

"EVERY has crossed the line from promise to proof," said Martin Davalos,
Partner & Head of Food Tech at McWin Capital Partners. "They're not
talking about proof-of-concept pilots here - they're selling metric tons of
product at scale to some of the biggest food companies on the planet. EVERY is
exactly the type of platform that will define the next decade of food
production."

 

Solving Traditional Supply Chain and Cost Instability

With egg prices swinging due to avian flu, supply issues, and higher feed
costs, food makers are looking for more reliable ingredients. EVERY's
fermentation tech provides a stable, cage-free-compliant source of egg protein
that performs as well as - or better than - conventional eggs.

 

Despite challenges across the alt-protein space, Elizondo says the core reason
for diversifying protein sources hasn't changed. "If the last two years have
taught us anything, it's that our current food system remains incredibly
fragile. One outbreak can wipe out hundreds of millions of hens. For food
companies small and large, that kind of risk just isn't tenable - and we now
have the answer."

 

EVERY's technology enables year-round, geographically flexible production that
is decoupled from livestock and feed markets and therefore completely devoid
of avian flu risk, supply shocks, and salmonella outbreaks. EVERY's proteins
are also shelf-stable, with an 18-month shelf life and have a powder format,
simplifying supply chain logistics and obviating the need for expensive cold
chains - a major advantage for bakeries across the world who rely on
refrigerated liquid eggs. The Company is consistently manufacturing metric
tons of product every month at commercial scale and rapidly expanding its
footprint which will enable it to reliably meet the demands of the world's
largest food brands.

 

"EVERY is proving what this technology can do - real products solving real
customer problems, at industrial scale, with a clear path to profitability,"
said Phil Morle, Partner at Main Sequence. "Their progress shows how
biomanufacturing has matured into a resilient, scalable part of the global
food supply chain. This is a massive opportunity to build the next generation
of food production."

 

ENDS

 

About Every™:

 

EVERY™ is a San-Francisco-based food technology company on a mission to
build a more secure and accessible global food system by supplying food and
beverage companies with egg protein ingredients made using precision
fermentation.

 

EVERY's line of innovative, FDA-approved ingredients includes OvoPro™
(ovalbumin, formerly EVERY EggWhite) which replaces the functionality of egg
and egg whites in a range of applications, and OvoBoost™ (formerly EVERY
Protein), a highly soluble, taste and texture neutral protein that can be used
to fortify a wide variety of food and beverage products including coffees,
juices, sodas, syrups, and baked goods.

 

For more on EVERY's B2B solutions transforming the food industry, visit
EVERY.com.

About Agronomics

Agronomics is a leading London-listed company focused on investment
opportunities within the field of cellular agriculture. The Company has
established a portfolio of over 20 companies developing technologies that
produce food and materials historically derived from animals, offering
solutions for improved sustainability, human health, and food security.

 

A full list of Agronomics' portfolio companies is available at
www.agronomics.im (http://www.agronomics.im) .

 

For further information, please contact:

 

 Agronomics Limited   Beaumont              Cavendish Capital     Peterhouse            33Seconds

                      Cornish Limited       Markets               Capital               Limited

                                            Limited               Limited
 The Company          Nomad                 Joint Broker          Joint Broker          Public Relations
 Jim Mellon           Roland Cornish        Giles Balleny         Lucy Williams         Jack Ferris

 Denham Eke           James Biddle          Michael Johnson       Charles Goodfellow    Amber Carr
 +44 (0) 1624 639396  +44 (0) 207 628 3396  +44 (0) 207 397 8900  +44 (0) 207 469 0936  agronomics@33seconds.co

 info@agronomics.im

About Reach announcements

 

This is a Reach announcement. Reach is an investor communication service aimed
at assisting listed and unlisted (including AIM quoted) companies to
distribute media-only / non-regulatory news releases into the public domain.
Information required to be notified under the AIM Rules for Companies, Market
Abuse Regulation or other regulation would be disseminated as an RNS
regulatory announcement and not on Reach.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAPKOBKOBDDDDK



            Copyright 2019 Regulatory News Service, all rights reserved